NEW YORK (GenomeWeb News) — NeoGenomics and Power3 Medical Products have formed a joint venture to create a contract research organization to sell Power3’s protein biomarker-based diagnostics, NeoGenomics said today.
Under the agreement, NeoGenomics has non-exclusively licensed all of Power3’s intellectual property for protein biomarkers. The diagnostics the companies plan to market will be based on “one or more” of these markers, NeoGenomics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.